Intravitreal Bevacizumab (Avastin®) in the Treatment of Neovascular Glaucoma - 18/08/11
, Diego Domig, MD, Ute Wolf-Schnurrbursch, MD, Sebastian Wolf, MD, Gian-Marco Sarra, MD
Inquiries to Milko E. Iliev, MD, Department of Ophthalmology, University of Bern, Inselspital, 3010 Bern, SwitzerlandRésumé |
Purpose |
To describe a case series of neovascular glaucoma (NVG) caused by central retinal vein occlusion (CRVO) that was treated with intravitreal bevacizumab (IVB; Avastin®).
Design |
Retrospective interventional case series.
Methods |
Six consecutive patients with NVG and a refractory, symptomatic elevation of intraocular pressure (IOP) and pronounced anterior segment congestion received IVB (1.25 mg/0.05 ml). Diode laser cyclophotocoagulation was carried out only if pressure was controlled insufficiently by topical medication. Follow-up examinations occurred at four to 16 weeks.
Results |
IVB resulted in a marked regression of anterior segment neovascularization and relief of symptoms within 48 hours. IOP decreased substantially in three eyes; in the other three eyes, adjuvant cyclophotocoagulation was necessary. No side effects were observed. Panretinal photocoagulation (PRP) was performed as soon as feasible, five to 12 weeks after IVB treatment.
Conclusion |
IVB leads to a rapid regression of iris and angle neovascularization and should be investigated more thoroughly as an adjunct in the management of NVG.
Le texte complet de cet article est disponible en PDF.Plan
Vol 142 - N° 6
P. 1054-1056 - décembre 2006 Retour au numéro
Article précédent
- Pediatric Ophthalmic Computed Tomographic Scanning and Associated Cancer Risk
- David M. Mills, Salina Tsai, Dale R. Meyer, Clifford Belden
- Assessment of Retinal Nerve Fiber Layer Using Optical Coherence Tomography and Scanning Laser Polarimetry in Progressive Glaucomatous Optic Neuropathy
- Mitra Sehi, David S. Greenfield
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?